Effects of Low Density Lipoprotein Apheresis on Oxidative Stress and Endothelial/Vascular Smooth Muscle Cell Function in Patients with Peripheral Arterial Disease and End-stage Renal Disease

Effects of Low Density Lipoprotein Apheresis on Oxidative Stress and Endothelial/Vascular Smooth Muscle Cell Function in Patients with Peripheral Arterial Disease and End-stage Renal Disease - Effects of LDL apheresis on ESRD patients with PAD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000652

Enrollment

Registered

2008-11-01

Start date

2007-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral artery disease, end-stage renal disease on hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The ESRD patients on hemodialysis who fulfilled the following criteria: 1. Ages from 20 to 80 years old, 2. Classified as > Fontaine class II, 3. Resistant to medication and/or difficult to perform PTA and/or bypass surgery.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Poor controlled diabetics, 2. Poor controlled hypertensives, 3. Moderate to severe liver dysfunction, 4. Judged as unsuitable from other reasons.

Design outcomes

Primary

Measure	Time frame
1. Clinical papameters 1) Signs & symptoms (pain at rest, intermittent claudication, walking distance) 2) Blood biochemistry (serum lipid including total cholesterol and LDL, coaglatory factors including fibrinogen, CRP, oxidised LDL, MDA-LDL, AGE, VEGF, HGF). 3) ABI/baPWV 2. Vascular cell functions 1) Human vascular endothelial cells (commercially available) (ecNOS expression, proliferative activity, tube formation activity) 2) Human vascular smooth muscle cells (commercially available)(expressions of AT1 receptor and its interacting molecule ATRAP, growth factors, extracellular matrix, proliferation activity).	—

Measure

Time frame

1. Clinical papameters 1) Signs & symptoms (pain at rest, intermittent claudication, walking distance) 2) Blood biochemistry (serum lipid including total cholesterol and LDL, coaglatory factors including fibrinogen, CRP, oxidised LDL, MDA-LDL, AGE, VEGF, HGF). 3) ABI/baPWV 2. Vascular cell functions 1) Human vascular endothelial cells (commercially available) (ecNOS expression, proliferative activity, tube formation activity) 2) Human vascular smooth muscle cells (commercially available)(expressions of AT1 receptor and its interacting molecule ATRAP, growth factors, extracellular matrix, proliferation activity).

—

Countries

Japan

Contacts

Public ContactKazuaki Uchino

Yokohama City University School of Medicine Department of Cardiorenal Medicine

uchinok@med.yokohama-cu.ac.jp045-787-2635

Outcome results